Longevity Biotech & Power Transformers: Two Industries That Could Make Your Kid a Millionaire

Two industries, two videos, same theme: this series is about places where demand for real human skills is exploding while everyone else is watching AI. First up, longevity biotech, a field with no commercial product yet and companies already paying scientists $1 million a year. Second, power transformers, the equipment nobody talks about that every AI data center, EV charger, and power plant needs to function, now stuck on a three-year waitlist. Here's what both fields actually look like right now, what the jobs pay, and where they're headed.

Altos Labs launched in 2022 with $3 billion behind it, backed by Jeff Bezos, Yuri Milner, and Arch Ventures. Its team includes Nobel laureate Shinya Yamanaka, and it has been recruiting university professors away from academia with salaries of $1 million a year or more.

Retro Biosciences, backed by Sam Altman, was valued at $1.8 billion as of May 2026. It's running a human clinical trial testing a pill designed to help Alzheimer's patients clear protein buildup in the brain, and its CEO said in mid-2026 that the trial is going well with no dose-limiting toxicities so far.

BioAge Labs is one of the few publicly traded companies in the space, listed on Nasdaq under the ticker BIOA since its 2024 IPO. It's currently running a Phase 2 trial combining its lead drug candidate with Eli Lilly's Zepbound for obesity in older adults.

Not every company in the space survives. Unity Biotechnology formally dissolved in 2025 after its eye treatment failed to outperform an existing drug in trials, laid off its entire workforce, and was delisted from Nasdaq. The field is genuinely early, and early means some of these bets don't pay off.

The anti-senescence therapy segment of the market is projected to reach $46.6 billion by 2033, growing at a compound annual rate of 6.5%. Broader definitions of the longevity biotech market that include epigenetic reprogramming put the number significantly higher.

Cellular biologists study how cells age, divide, and break down, which is the foundational science behind almost every longevity therapy in development. Entry-level pay starts around $42,500 to $45,000. Mid-career cellular biologists average $68,700 to $73,900, and experienced researchers in the field can earn up to $157,000.

Biochemists run the lab work that turns a theory about aging into an actual drug candidate. The average biotech research scientist earns $130,117 a year, and pharmaceutical and biotech companies specifically pay a median of $222,039 for cell biology research scientist roles, the highest of any industry that employs this specialty.

Clinical research associates run and monitor the human trials that decide whether a longevity drug actually works, managing everything from patient safety data to regulatory paperwork. Average pay is $99,000 to $114,000, with the pharma and biotech sector paying a median of $107,268, among the highest-paying industries for this role.

Computational biologists use code and machine learning to make sense of the genetic and cellular data these companies generate, and it's one of the fastest-growing entry points into the field for people with a software or data background rather than a pure lab background. Entry-level pay runs $90,000 to $115,000, mid-level $125,000 to $170,000, and senior computational biologists at top biotech companies earn $180,000 to $250,000 or more in hubs like the Bay Area, Boston, and San Diego.

Biochemists, biophysicists, medical scientists, and biological technicians as a group are projected to grow 7% to 11% over the next decade, well above the 5% average growth rate for all US occupations. Biotech R&D specifically added 10,700 jobs in the first ten months of 2024 alone, a 3.7% increase that pushed the subsector to a record workforce of 303,000. Industry analysts expect 2026 to bring a leveling off of the layoffs that hit biotech in 2025, with some predicting modest headcount growth as interest rates ease and healthcare sentiment improves.

None of these roles require betting on a single company surviving. They require a real science or technical background: chemistry, biology, biochemistry, or computer science with a biology minor. If there's a kid in your life still deciding what to study, cellular biology, biochemistry, clinical research, and computational biology are four different doors into the same fast-growing field, and none of them require knowing in advance which specific company wins.

Power transformers are the unglamorous equipment that steps electricity up or down so it can move safely across the grid. Almost nobody outside the utility industry thought about them two years ago. Now they're the single biggest bottleneck standing between the AI boom and the power it needs to run.

Lead times for large power transformers have stretched past 128 weeks, and generator step-up transformers, the units used to connect new power plants to the grid, are now averaging 144 weeks, with some utility quotes running as long as four years out.

This is as much a demand problem as a supply one. Demand for generator step-up transformers has surged 274% since 2019, and demand for substation power transformers is up 116% over the same stretch, as AI data centers, EV charging buildout, and industrial electrification all compete for the same limited pool of transformer-grade steel and copper.

Prices have moved just as fast. Power transformer prices are up roughly 77% to 80% since 2019, and some distribution transformer classes have jumped as much as 95%. Industry analysts estimate the US market is short by roughly 30% of the power transformers utilities actually need to keep up with demand.

Manufacturers are racing to close the gap. Hitachi Energy, the world's largest transformer manufacturer by installed base, portfolio, and manufacturing capacity, is investing an additional $1.5 billion to expand global transformer production by 2027 and add 4,000 jobs to its transformer business alone. Siemens Energy, publicly traded and one of the largest grid equipment suppliers on the planet, is expanding its own transformer capacity, including a new plant in North Carolina. GE Vernova is one of several manufacturers behind nearly $1.8 billion in newly announced North American transformer manufacturing expansions, including an expanded Pennsylvania facility built specifically to shorten lead times on critical grid components.

Electrical engineers design the systems that generate, transmit, and control power, which puts them at the center of every transformer and grid project in development. The median annual wage for electrical engineers was $111,910 as of May 2024, and the Bureau of Labor Statistics projects 7% employment growth through 2034, well above average, with about 13,800 new electrical engineering positions opening up over the decade.

Materials engineers develop the specialty steel, copper alloys, and insulation that make transformers possible, and they're one of the reasons transformer manufacturing can't just scale up overnight. The median annual wage for materials engineers was $108,310 as of May 2024, with 6% projected growth through 2034 and about 1,500 openings a year, a smaller but fast-growing field.

Every transformer factory, substation, and data center still needs to be physically built, wired, and maintained, and that work falls to the trades. Electricians earn a median $62,350 a year, with the BLS projecting 9% growth through 2034, much faster than average, and about 81,000 openings a year. Welders earn a median $51,000, with slower 2% projected growth but still roughly 45,600 openings a year as retirements outpace new entrants. Plumbers and pipefitters earn a median $62,970, with 4% projected growth and about 44,000 openings a year. None of these roles require a four-year degree, and all three are in higher demand than most white-collar entry points into this boom.

This isn't a short-term spike. Utilities, hyperscalers, and manufacturers are all planning around lead times measured in years, not months, and the capacity investments announced by Hitachi Energy, Siemens Energy, GE Vernova, and others won't fully close the gap until 2027 or 2028 at the earliest. Power demand from AI data centers alone is projected to keep climbing well past that point, which means the transformer shortage, and the hiring boom behind it, is likely to outlast this news cycle by years.

Everyone is talking about the AI boom. Almost nobody is talking about the power it takes to run it, or the fact that building out that power grid is really a trades boom wearing a tech-story costume. If there's a kid in your life deciding what to study or where to apprentice, electrical engineering and materials science are two real, technical doors into this field, and a skilled trade like electrical work, welding, or plumbing is a third door that pays well, is in chronic shortage, and doesn't require a college degree or betting on which manufacturer wins.